Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial
Bruno François(Inserm), Sébastien Gibot(Centre Hospitalier Régional et Universitaire de Nancy), Pierre Asfar(Centre Hospitalier Universitaire d'Angers), Cédric Darreau, Julio Badié(Assistance Publique – Hôpitaux de Paris), Marc Derive, Jean–Jacques Garaud, Jérémie Lemarie(Association de Recherche en Soins Infirmiers), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Jean-Claude Lachérade(Roche (France)), Tom Fivez(Ziekenhuis Oost-Limburg), Simon Lambden(University of Cambridge), Valérie Cuvier, Christophe Vinsonneau(Centre Hospitalier de Béthune), Margarita Salcedo‐Magguilli, Jean‐Pierre Quenot(Inserm), Jean‐Paul Mira(Hôpital Cochin), Anne-Lise Laszlo-Pouvreau, Emmanuelle Mercier(Centre Hospitalier Universitaire de Tours), Mitchell M. Levy(Brown University), Jean‐Marie Grouin(Université de Rouen Normandie), Julie Helms(Inserm)
Cited by 18
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k